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Infiltrating immune cells are a key component of the tumor microenvironment and play
central roles in dictating tumor fate, either promoting anti-tumor immune responses, or
sustaining tumor growth, angiogenesis and metastasis. A distinctive microenvironment
is often associated to different tumor types, with substantial differences in prognosis. The
production of a variety of chemotactic factors by cancer and stromal cells orchestrates
cell recruitment, local immune responses or cancer progression. In the last decades,
different studies have highlighted how chemotactic cues, and in particular chemokines,
can act as natural antagonists or induce synergistic effects on selective receptors
by forming heterocomplexes, thus shaping migratory responses of immune cells. A
variety of chemokines has been described to be able to form heterocomplexes both
in vitro and in vivo under inflammatory conditions, but nowadays little is known on
the presence and relevance of heterocomplexes in the tumor microenvironment. In
recent years, the alarmin HMGB1, which can be massively released within the tumor
microenvironment, has also been described to form a complex with the chemokine
CXCL12 enhancing CXCR4-mediated signaling, thus providing an additional regulation
of the activity of the chemokine system. In the present review, we will discuss the current
knowledge on the synergy occurring between chemokines or inflammatory molecules,
and describe the multiple functions exerted by the chemokines expressed in the tumor
microenvironment, pointing our attention to the synergism as a possible modulator of
tumor suppression or progression.
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INTRODUCTION
The leukocyte infiltrate is a key component of the cancer stromal compartment. Within the
tumor, the wide range of chemokines produced by both malignant and stromal cells can affect
the composition and the phenotype of the cell infiltrate, and influence tumor growth, survival
and metastasis (1–5). Chemokines that regulate leukocyte migration and play key roles in both
physiology and pathological conditions (6–8), are small proteins of 8–12 KDa, which can be
divided into 4 groups (CCL-, CXCL-, CX3CL1, and XCLs chemokines) according to the position
of two conserved cysteine residues within their structure. The chemokine system is characterized
by a set of almost 50 ligands, which engage in a promiscuous fashion a panel of more than 20
chemokine receptors, including conventional and atypical receptors, expressed by immune cells,
D’Agostino et al. Chemokines in Tumor Microenvironment
endothelial cells and cancer cells (9–12). The promiscuous
pattern of interaction, together with the large number of ligands
and receptors, enables the chemokine system to mediate a variety
of cell functions. This is of particular relevance in tumors,
since chemokines can influence angiogenesis, cell-adhesion, cell
extravasation, and survival (7). Different chemokines can also
interact together showing antagonistic or synergistic activity on
specific chemokine receptors. They can trigger simultaneously
different receptors, resulting either in the inhibition or in the
enhancement of the intracellular cell signaling (13, 14), or a single
receptor can be activated by a heterocomplex formed between
two chemokines, resulting in a stronger cellular response (13, 15).
Additionally, chemokines can also interact with inflammatory
mediators released in the microenvironment, amplifying cellular
responses induced by chemokine receptors (16, 17).
While the multiple roles of heterocomplexes in the early stage
of inflammation and in regeneration have been clearly dissected
(13, 18, 19), little is known about their functions in tumors (20),
and further studies are necessary to define their significance.
Von Hundelshausen and colleagues have performed a thorough
study mapping the chemokine heterocomplexes by bidirectional
immunoligand blotting (21). This study opens the debate on
the in vivo relevance of the multitude of heterocomplexes
found in vitro. In the present review, we discuss examples on
how the concomitant expression of several chemokines with
either anti- or pro-tumor functions could favor heterocomplexes
formation in the tumor microenvironment (TME), thus adding
an additional feature to be considered in tumor immunity.
CHEMOKINE HETEROCOMPLEXES
Several studies in the last decade have described the
heterodimerization between chemokines as a regulatory
mechanism that governs their activity under inflammatory
conditions. In the TME, chemokines play crucial roles either
favoring immune responses against the tumor or promoting
cancer progression and metastasis. Of note, similar chemokine
expression profiles can result in a different tumor-specific
leukocyte infiltrate. This phenomenon suggests that additional
regulatory mechanisms might be involved, including the release
of proteins able to modify chemokine activity. It is now well
established that a chemokine receptor can be triggered by a low
concentration of its selective agonist when a synergy-inducing
chemokine, not selective for the receptor but able to form a
complex with the agonist, is concomitantly present (17, 22, 23)
(Table 1). The first evidence of the synergism induced by
the presence of two chemokines was provided by Struyf and
colleagues (24), who described the synergy between Regakine-1
and CXCL8, and between Regakine-1 and CCL7. Few years later,
the same group has shown that CXCL8 can enhance CXCL12
responses and this enhancement is CXCR4 mediated (25). In
2005, three groups described the formation of heterocomplexes
between chemokines, able to enhance the activity of CCR7,
CCR4, CCR5, and CXCR2 (23, 26, 29, 30). In particular, CXCL13
forms a complex with CCL19 and CCL21, leading to CCR7
activation at lower agonist concentrations (23). The CXCR3-
TABLE 1 | Synergy-inducing chemokines heterocomplexes .
Receptor Heterocomplexes Synergistic Functions References
CXCR1/2 CXCL8/Regakine-1
CXCL8/CXCL4
CXCL7/Regakine-1
Chemotaxis of neutrophils and of
CXCR1-transfected Jurkat cells.
(24–27)
CCR7*
CXCR5
CCL19/CXCL13
CCL21/CXCL13
CXCL13/CCL19
CXCL13/CCL21
Chemotaxis of CCR7+
transfected PreB cells and
human leukocytes (DCs, B and T
lymphocytes).
Increased chemotaxis of CCR7+
Sezary Syndrome (SS) cells.
(23, 28)
CCR4** CCL22/CXCL10
CCL22/CCL19
CCL17/CXCL10
and many others
Chemotaxis of human T
lymphocytes (Th1-Th2).
(29)
CCR5 CCL5/CXCL4 Triggering of monocytes arrest
on activated endothelium under
flow conditions.
Blockade of CCL5/CXCL4
heterocomplex inhibits
atherosclerosis in hyperlipidemic
mice.
(30, 31)
CCR2 CCL2/CCL19
CCL2/CCL21
CCL7/CCL19
CCL7/CCL21
CCL7/Regakine-1
Induction of chemotaxis and
responses in monocytes and
lymphocytes.
(24, 32)
CXCR4 CXCL12/CXCL9 Recruitment of tumor-infiltrating
lymphocytes in primary central
nervous system lymphoma.
(20)
CXCR4 CXCL12/HMGB1 Promotion of monocytes
chemotaxis both in vitro and
in vivo.
Tissue regeneration (liver,
muscle, bone).
(16, 18, 19)
* Additional CXC and CC chemokines have been shown in this study to act in synergy
with the selective CCR7 agonists. Migration is enhanced in human mature dendritic cells,
B cells, T cells, and CCR7-transfected cells.
** Additional CXC and CC chemokines have been shown in this study to act in synergy
with CCL22. Migration is enhanced in CCR4-transfected cells.
and CCR4-agonists, CXCL10 and CCL22, co-expressed in the
inflamed skin, synergistically interact together, through the first
β-strand of CCL22, enhancing CCR4-mediated chemotaxis of
T cells, independently from CXCR3 or GAGs binding (29).
Other studies showed that the heterocomplex between CCL5
and CXCL4, formed through heterophilic interactions, plays a
crucial role in triggering monocyte arrest on the endothelium
(30). In this case, the authors demonstrated the requirement of
GAGs on the cell surface, and that the CCL5/CXCL4 complex
showed paired N-terminus, resembling a CC-type heteromer
that promoted a more efficient receptor activation (30, 31).
NMR spectroscopy and molecular modeling, followed by in vitro
analysis, have shown the structure of a heterocomplex between
CXCL8 and CXCL4. This complex was shown to enhance the
anti-proliferative effect of PF4 on endothelial cells, and the
CXCL8-induced migration of CXCR2 transfected cells (26).
Later on, the CCR7-agonists, CCL19 and CCL21, were
described as enhancer of monocytes recruitment by forming
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heterocomplexes with CCL7 and CCL2, resulting in an
augmented CCR2 response, and preventing CCL7 and CCL2
degradation by ACKR2 (32).
A study directly supporting the idea that the activity of
heterocomplexes can be relevant also in cancer was performed
in our laboratory, showing the role of the CXCL9/CXCL12
heterocomplex in primary central nervous system lymphoma
(PCNSL). In this work, it was shown that CXCL9 and
CXCL12 are co-expressed in the perivascular area of the
tumor, and can form a complex enhancing CXCR4-mediated
recruitment of tumor-infiltrating lymphocytes and malignant B
cells. This synergism might serve as regulator of the recruitment
of CD8+/CXCR4+/CXCR3+ T cells and CXCR4+/CXCR3-
malignant B cells in the perivascular cuffs, forming the typical
lesions of these tumors (20).
CXCL12/HMGB1 HETEROCOMPLEX
A synergism, mediated by the heterocomplex formed between
CXCL12 and the DAMP protein HMGB1 has been shown to
be relevant in monocyte recruitment (16, 33) and in tissue
regeneration (19, 34). However, its involvement in modulating
tumor progression and metastasis has never been assessed.
Nonetheless, both CXCL12 and HMGB1 are key players in
the TME, where they orchestrate a variety of functions that
sustain cancer progression. Indeed, the CXCL12/CXCR4 axis
is hyper-activated in lymphomas and in many solid tumors.
Their activity is central in the promotion of tumor progression
and metastasis to the lungs, brain and bone (35, 36). HMGB1
plays a variety of functions based on its cellular location: in the
nucleus, is essential for nucleosomes dynamics and chromosomal
stability; in the cytosol or mitochondria, modulates autophagy
and apoptosis and regulates mitochondrial morphology and
functions; on the cell surface of neurons, promotes axon
sprouting and neurite outgrowth (37). Stressed and cancer cells
release HMGB1 in the extracellular space, where it activates
different receptors in a redox-sensitive manner. The disulphide-
HMGB1 promotes TLR-4 activation and mediates production of
inflammatory cytokines and chemokines, whereas the reduced-
HMGB1 triggers RAGE to promote autophagy and CXCL12
secretion. The reduced form is also able to complex with
CXCL12 mediating CXCR4-dependent chemotaxis (33, 38). The
CXCL12/HMGB1 heterocomplex acts as an enhancer of CXCR4-
mediated signaling, potentiating ERK activation, calcium rise and
chemotaxis, both in vitro and in vivo (17). The effect can be
blocked by glycyrrhizin and by anti-CXCL12 antibodies, which
prevent the formation of the heterocomplex, or by AMD3100,
proving the sole involvement of CXCR4 (16, 39). Moreover, the
heterocomplex induces a rearrangement of the N-terminus of
CXCL12 and conformational changes in the CXCR4-dimers (16)
that might suggest a different mode of receptor triggering.
Recently an important role of the CXCL12/HMGB1
heterocomplex has been described in tissue regeneration. Fully
reduced HMGB1 promotes liver and muscle regeneration
through CXCR4, by acting on muscle stem cells, hepatocytes,
and infiltrating cells (18). In a similar study, HMGB1 was
detected after fracture both in humans and in animal models,
and the heterocomplex acting via CXCR4 promotes in vivo
skeletal, hematopoietic and muscle regeneration (19).
CHEMOKINE FUNCTIONS IN THE TUMOR
MICROENVIRONMENT
During the different phases of cancer progression, many types
of inflammatory cells that exhibit either anti- or pro-tumoral
functions are recruited from the blood stream by specific
chemotactic cues. The leukocyte infiltrate includes neutrophils
with different phenotypes (40), macrophages (41), natural killer
cells (NK) (42), myeloid-derived suppressor cells (MDSC) (43,
44), dendritic cells (DCs) (45), T and B lymphocytes (46, 47).
Several chemokines have been shown to be expressed in tumors,
guiding leukocyte recruitment and positioning, and to support
tumor spread at distal organs (7). Below we provide some
examples in which different cell types present in tumors can be
recruited in the TME thanks to the activity of chemokines, and
possibly to the presence of heterocomplexes.
Anti-tumoral Functions
Chemokines mediate anti-tumor activities through the
recruitment of specific immune cell types (48). CXCL9 and
CXCL10, agonists of the CXCR3, promote the recruitment
of CD4+ Th1 lymphocytes, NK cells, and CD8+ cytotoxic T
lymphocytes (CTL) to the TME, where they exert a potent anti-
tumor activity (7, 49). Th17 cells further sustain the recruitment
of CTL, NK cells (50), and DCs (51). In particular, CTL specific
for tumor-associated antigens (TAA), together with Th1 and
NK cells expressing IFNγ, guide immunity against the tumor
promoting tumor cell apoptosis, and releasing effector cytokines
and cytotoxic molecules (48). Indeed, evidence in patients with
ovarian cancer demonstrated that the increased expression of
CXCL9 and CXCL10 correlates with an increased number of
tumor-infiltrating CTL and a high CD8+/regulatory T cells
ratio that lead to a reduction in cancer metastasis and to a
better prognosis (52). IFNγ produced within the TME induces
CXCL9, CXCL10, and CXCL11 expression, which correlates with
tumor infiltrating CTL and Th1-effector cells and with a positive
survival rate in colorectal cancer (53). Moreover, the presence of
CTL, CXCL9, and CXCL10 within the tumors is associated to a
positive response to PD1/PD1L blocking therapies (54, 55). In
recent years, Bronger and colleagues demonstrated that CXCL9
and CXCL10 expression can predict survival in high-grade
serous ovarian cancer patients (56).
Tumor tissues from ovarian cancer patients show a dynamic T
cell infiltration at different disease stages. Th17 and Th1 cells are
present in the early stages, associated with an anti-tumor immune
response and production of CXCL9 and CXCL10 (56). In the later
stages Treg, expressing CCR4, correlate with CCL22 production,
and are associated to pro-tumoral immunosuppressive functions
(57). The role of the CCL22/CXCL10 heterocomplex (29) in
the switch from an anti- to a pro-tumoral TME should be
investigated.
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CXCL9 and CXCL12 can form heterocomplexes, and in
PCNSL are coexpressed on the tumor vasculature. CXCL12-
induced migration is enhanced in CXCR4+/CXCR3+/CD8+
T lymphocytes and in CXCR4+/CXCR3− malignant B cells,
indicating that chemotactic cues in the perivascular environment
serve as regulators for the recruitment of tumor infiltrating
lymphocytes (TILs) (20). Tumor associated macrophages (TAM)
are also a source of CXCL9 and CXCL12. Interestingly, the
expression of CXCL9 is restricted to macrophages present in the
perivascular area, indicating heterogeneity among macrophages
within the tumor, and suggesting this cell type as the most
important player for the recruitment of CTL in the perivascular
space (20).
TAM, recruited to the tumor in response to chemokines,
polarize toward different subtypes (M1 or M2) accordingly to
the presence of activating stimuli generated by the cytokines
expressed in the microenvironment. M1 macrophages produce
CXCL9 and CXCL10 and exert an anti-tumoral activity, whileM2
macrophages sustain cancer growth (5, 41, 58). CXCR3 agonists
are also important for the polarization toward a M1 phenotype,
since CXCR3 deficiency of this receptor induces a M2 phenotype
(59).
Tumor associated neutrophils (TAN) polarized toward a
N1 phenotype exert an anti-tumoral activity. In particular,
TGF-β blockade increased neutrophil attracting chemokines
(CXCL2, CXCL5, CCL3) specific for CXCR1/2 and CCR2-5. This
resulted in an influx of CD11b+/Ly6G+ TAN with enhanced
tumor cytotoxic activities and higher levels of pro-inflammatory
cytokines (60).
The expression of CCR5 on CD4+ and CD8+ T lymphocytes
has been described to be essential for an efficient tumor rejection
in mouse model of Lewis lung adenocarcinoma and pancreatic
adenocarcinoma (61). The activity of CCL5, a selective CCR5
agonist, can be enhanced by CXCL4 (30), a chemokine expressed
by a variety of tumor types (62). Interestingly, in both tumor
types the expression of CXCL4 have been documented (62),
and could represent an additional tool for enhancing CCR5
responses.
The recruitment of other cell types including DCs and B cells
with antigen presenting functions is essential for the expansion
and activation of leukocytes within the TME (48). High
levels of B cell-infiltrates, recruited into the microenvironment
through the CXCL12/CXCR4 axis, are positively associated
with a good survival rate in breast cancer, high-grade serous
ovarian cancer, and cervical cancer (63–65). B cells infiltrating
the tumor can organize in tumor-associated tertiary lymphoid
structures, where they act as antigen presenting cells enhancing
T cell responses or producing tumor-specific antibodies (66).
In breast cancer, a specific subset of T follicular helper cells,
through the production of CXCL13, has been linked to tertiary
lymphoid structures formation, generation of germinal centers
and maturation of B cells, migrating into the TME via CXCR5
(67).
A recent study showed that NK cells, through the production
of CCL5 and XCL1, recruit DCs into the TME promoting cancer
immune control, which is associated with patient survival (68).
Pro-Tumoral Functions
Chemokines can also support tumor progression and metastasis,
either acting as angiogenic factors (69), or through the
recruitment of different immune cell types into the TME, which
inhibit effector cell functions (7, 48).
Within the CXC-family of chemokines, an important role in
inducing angiogenesis has been demonstrated for chemokines
containing the ELR motif (glutamic acid-leucine-arginine).
Neovascolarization is an essential process that sustains solid
tumor growth and metastasis. In humans, CXCR2 is considered
the receptor mainly involved in angiogenesis through the
interaction with ELR+ chemokines (CXCL1, CXCL2, CXCL3,
CXCL5, CXCL6, CXCL7, and CXCL8). CXCR2 activity has been
directly correlated with the aggressiveness of a number of tumors,
includingmelanoma (70), pancreatic cancer (71), gastrointestinal
cancers (72), and renal cell carcinoma (73).
CCL22 and CCL28, expressed in many human tumors, are
mediators for the recruitment of CCR4+/CCR10+ Treg cells,
involved in the suppression of both spontaneous and therapy-
induced local tumor immunity. The presence of these cells is
associated to a poor prognosis (74–76). It has been demonstrated
also that Treg directly support angiogenesis through the secretion
of VEGF and promote metastasis via the induction of NK
cells apoptosis (75, 77). Interestingly, the expression of CXCR3
by Treg resulted in an immunosuppressive effect mediated by
the control of Th1-associated responses (78). In addition, Treg
with a memory phenotype are frequently recruited through
CXCR4/CXCL12 signaling to the bone marrow, a common target
of metastasis in humans, further supporting the idea that this cell
subset provides an anti-inflammatory environment that sustains
cancer progression (79, 80).
Th22 cells, that under physiological conditions express
CCR10, CCR6 and CCR4, and home to the skin (81), have
been shown to be recruited to the tumor site, supporting
tumorigenesis through the activation of STAT3 and the
enhancement of the expression of the methyltransferases
DOT1L (82) and of the Polycomb repressive complex 2
(PRC2) (83). B cells, as well, can exert a regulatory function
by inhibiting T cells activity through the production of
TGF-β and IL-10, or further support tumorigenesis via the
production of TNF (84, 85). Their recruitment to the tumor
sites is mediated by the CXCL12/CXCR4 axis, and might be
enhanced by the chemokines known to form a complex with
CXCL12.
Myeloid-derived suppressor cells (MDSCs) are deeply
investigated in tumor models and in cancer patients, due to
their relevant role in promoting cancer stemness (43, 44).
Granulocytic MDSCs, mainly composed by different subsets of
neutrophils, express CXCR1 and CXCR2, and are recruited to
the tumor by CXCL8, produced by tumor cells or by Treg (86).
In the TME, they release molecules that sustain angiogenesis,
further supporting tumor progression and metastasis (44).
Interestingly, CXCL8 has been shown to synergize with CXCL4,
which is produced by a variety of tumors at different stages
(62). Monocytic MDSCs, that include macrophages at different
maturation stages, express CCR2, CXCR2 and CXCR4, and can
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reach the tumor via their specific ligands CCL2, CXCL5 and
CXCL12 respectively (87, 88). These cells are able to sustain
tumor growth via the induction of arginase-I, iNOS, and TGF-β,
and favor the recruitment of Treg at the tumor site through the
production of CCR5-binding chemokines (89).
The M2 subset of TAM is negatively correlated with survival
in cancer, and is associated with responses that sustain tumor
growth and progression (41, 90).
Plasmacytoid DCs can reach the TME via the
CXCR4/CXCL12 axis. Their recruitment sustains tumor
growth by the induction of IL-10 producing Treg that in turn
suppress the activation of tumor specific effector T cells (91, 92).
As shown by Vanbervliet and colleagues, the sensitivity of this
cell type to CXCL12 can be enhanced by the CXCR3 agonists
(93). Nonetheless, this type of synergy was interpreted as the
activity of both CXCR4 and CXCR3, and was not demonstrated
if this effect was due to a heterocomplex formation, as shown
later in the PCNSL (20).
CONCLUSIONS
Many chemokines are abundantly and concomitantly expressed
in the TME and orchestrate a variety of functions that
sustain cancer progression or suppression. While the activity
of chemokine heterocomplexes has been deeply investigated in
inflammatory conditions, and in models of tissue regeneration, a
direct prove that a heterocomplex can enhance the responses of
tumor cells to chemokines has been demonstrated only for the
CXCL12/CXCL9 heterocomplex in PCNSL (20). The concepts
covered in the present review suggest that the nature and function
of tumor infiltrating immune cells might not be the simple
result of the interaction occurring between a chemokine agonist
and its specific receptor, but, could be mediated by chemokine
heterocomplexes that can differently modulate the activation of
a variety of chemokine receptors regulating cell recruitment,
positioning, and the switch in the components of the cellular
infiltrate in different tumor stages.
The mapping of the possible chemokine-chemokine
interactions by bidirectional immunoligand blotting suggests
that the synergism might preferentially be mediated by CC-type
heterodimers, whereas the CXC-types might promote inhibitory
effects (21). Additional studies are required to determine whether
this distinction can be applied to the whole chemokine system,
and in particular if the heterocomplexes identified are relevant in
the TME.
As testified by the diverse expression of chemokine receptors
in tumors and by the multiple activities of the heterocomplexes
studied so far, we might expect different responses to the same
heterocomplex according to the distinctive features of each TME.
A deeper understanding of the modulation of the chemokine
system in TME, will tell us the relevance of the heterocomplexes,
and their possible involvement in shaping the activity of the
microenvironment.
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
FUNDING
The studies on the modulation of chemokines activities were
supported by the Swiss National Science Foundation (3100A0-
143718/1), by the San Salvatore Foundation, by the European
Union’s Programs for research, technological development and
demonstration under grant agreements, DEC-VAC-LSHP-CT-
2005-018685 (FP6), MD-THIV-235200 (FP7-IEF), ADITEC-
280873 (FP7), and TIMER-281608 (FP7). Further support was
obtained by the Helmut Horten Foundation.
ACKNOWLEDGMENTS
Special thanks to Gabriela Danelon for her excellent technical
support to our work on the synergism of the chemokine system.
REFERENCES
1. Balkwill F. Chemokine biology in cancer. Semin Immunol. (2003) 15:49–55.
doi: 10.1016/S1044-5323(02)00127-6
2. Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur
J Cancer (2006) 42:760–7. doi: 10.1016/j.ejca.2006.01.002
3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation.
Nature (2008) 454:436–44. doi: 10.1038/nature07205
4. Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines
in cancer related inflammation. Exp Cell Res. (2011) 317:664–73.
doi: 10.1016/j.yexcr.2010.11.013
5. Del Prete A, Schioppa T, Tiberio L, Stabile H, Sozzani S. Leukocyte
trafficking in tumor microenvironment. Curr Opin Pharmacol. (2017)
35:40–7. doi: 10.1016/j.coph.2017.05.004
6. Charo IF, Ransohoff RM. The many roles of chemokines and
chemokine receptors in inflammation. N Engl J Med. (2006) 354:610–21.
doi: 10.1056/NEJMra052723
7. Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. (2014)
2:1125–31. doi: 10.1158/2326-6066.CIR-14-0160
8. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine
receptors: positioning cells for host defense and immunity. Annu Rev
Immunol. (2014) 32:659–702. doi: 10.1146/annurev-immunol-032713-1
20145
9. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM,
Graham GJ, et al. International union of pharmacology. LXXXIX. Update
on the extended family of chemokine receptors and introducing a new
nomenclature for atypical chemokine receptors. Pharmacol Rev. (2014)
66:1–79. doi: 10.1124/pr.113.007724
10. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima
K, et al. International union of pharmacology. XXII. Nomenclature for
chemokine receptors. Pharmacol Rev. (2000) 52:145–76.
11. Moratz C, Kang VH, Druey KM, Shi CS, Scheschonka A, Murphy PM,
et al. Regulator of G protein signaling 1 (RGS1) markedly impairs Giα
signaling responses of B lymphocytes. J Immunol. (2000) 164:1829–38.
doi: 10.4049/jimmunol.164.4.1829
12. Bachelerie F, Graham GJ, Locati M, Mantovani A, Murphy PM, Nibbs R, et al.
New nomenclature for atypical chemokine receptors. Nat Immunol. (2014)
15:207–8. doi: 10.1038/ni.2812
Frontiers in Immunology | www.frontiersin.org 5 September 2018 | Volume 9 | Article 2185
D’Agostino et al. Chemokines in Tumor Microenvironment
13. Proudfoot AE, Uguccioni M. Modulation of chemokine responses:
synergy and cooperativity. Front Immunol. (2016) 7:183.
doi: 10.3389/fimmu.2016.00183
14. De Buck M, Gouwy M, Berghmans N, Opdenakker G, Proost P, Struyf S, et al.
COOH-terminal SAA1 peptides fail to induce chemokines but synergize with
CXCL8 and CCL3 to recruit leukocytes via FPR2. Blood (2018) 131:439–49.
doi: 10.1182/blood-2017-06-788554
15. Gouwy M, Schiraldi M, Struyf S, Van Damme J, Uguccioni M. Possible
mechanisms involved in chemokine synergy fine tuning the inflammatory
response. Immunol Lett. (2012) 145:10–4. doi: 10.1016/j.imlet.2012.
04.005
16. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, et al.
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by
forming a complex with CXCL12 and signaling via CXCR4. J Exp Med. (2012)
209:551–63. doi: 10.1084/jem.20111739
17. Cecchinato V, D’Agostino G, Raeli L, Uguccioni M. Chemokine interaction
with synergy-inducing molecules: fine tuning modulation of cell trafficking.
J Leukoc Biol. (2016) 99:851–5. doi: 10.1189/jlb.1MR1015-457R
18. Tirone M, Tran NL, Ceriotti C, Gorzanelli A, Canepari M, Bottinelli R, et al.
High mobility group box 1 orchestrates tissue regeneration via CXCR4. J Exp
Med. (2018) 215:303–18. doi: 10.1084/jem.20160217
19. Lee G, Espirito Santo AI, Zwingenberger S, Cai L, Vogl T, Feldmann M,
et al. Fully reduced HMGB1 accelerates the regeneration of multiple tissues
by transitioning stem cells to GAlert. Proc Natl Acad Sci USA. (2018)
115:E4463–72. doi: 10.1073/pnas.1802893115
20. Venetz D, Ponzoni M, Schiraldi M, Ferreri AJ, Bertoni F, Doglioni C, et al.
Perivascular expression of CXCL9 and CXCL12 in primary central nervous
system lymphoma: T-cell infiltration and positioning of malignant B cells. Int
J Cancer (2010) 127:2300–12. doi: 10.1002/ijc.25236
21. Von Hundelshausen P, Agten SM, Eckardt V, Blanchet X, Schmitt MM,
Ippel H, et al. Chemokine interactome mapping enables tailored intervention
in acute and chronic inflammation. Sci Transl Med. (2017) 9:eaah6650.
doi: 10.1126/scitranslmed.aah6650
22. Gouwy M, Struyf S, Proost P, Van Damme J. Synergy in cytokine and
chemokine networks amplifies the inflammatory response. Cytokine Growth
Factor Rev. (2005) 16:561–80. doi: 10.1016/j.cytogfr.2005.03.005
23. Paoletti S, Petkovic V, Sebastiani S, Danelon MG, Uguccioni M, Gerber BO.
A rich chemokine environment strongly enhances leukocyte migration and
activities. Blood (2005) 105:3405–12. doi: 10.1182/blood-2004-04-1648
24. Struyf S, Proost P, Lenaerts JP, Stoops G, Wuyts A, Van Damme J.
Identification of a blood-derived chemoattractant for neutrophils and
lymphocytes as a novel CC chemokine, regakine-1. Blood (2001) 97:2197–204.
doi: 10.1182/blood.V97.8.2197
25. Gouwy M, Struyf S, Catusse J, Proost P, Van Damme J. Synergy
between proinflammatory ligands of G protein-coupled receptors in
neutrophil activation and migration. J Leukoc Biol. (2004) 76:185–94.
doi: 10.1189/jlb.1003479
26. Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, et al.
Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation
modulates function at the quaternary structural level. J Biol Chem. (2005)
280:4948–58. doi: 10.1074/jbc.M405364200
27. Gouwy M, Struyf S, Mahieu F, Put W, Proost P, Van Damme
J. The unique property of the CC chemokine regakine-1 to
synergize with other plasma-derived inflammatory mediators
in neutrophil chemotaxis does not reside in its NH2-terminal
structure. Mol Pharmacol. (2002) 62:173–80. doi: 10.1124/mol.62.
1.173
28. Picchio MC, Scala E, Pomponi D, Caprini E, Frontani M, Angelucci I, et al.
CXCL13 is highly produced by Sezary cells and enhances their migratory
ability via a synergistic mechanism involving CCL19 and CCL21 chemokines.
Cancer Res. (2008) 68:7137–46. doi: 10.1158/0008-5472.CAN-08-
0602
29. Sebastiani S, Danelon G, Gerber B, Uguccioni M. CCL22-induced responses
are powerfully enhanced by synergy inducing chemokines via CCR4: evidence
for the involvement of first beta-strand of chemokine. Eur J Immunol. (2005)
35:746–56. doi: 10.1002/eji.200525800
30. Von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W,
Proudfoot AE, et al. Heterophilic interactions of platelet factor 4 and
RANTES promote monocyte arrest on endothelium. Blood (2005) 105:924–
30. doi: 10.1182/blood-2004-06-2475
31. Koenen RR, Von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA,
Sarabi A, et al. Disrupting functional interactions between platelet chemokines
inhibits atherosclerosis in hyperlipidemic mice. Nat Med. (2009) 15:97–103.
doi: 10.1038/nm.1898
32. Kuscher K, Danelon G, Paoletti S, Stefano L, Schiraldi M, Petkovic V, et al.
Synergy-inducing chemokines enhance CCR2 ligand activities on monocytes.
Eur J Immunol. (2009) 39:1118–28. doi: 10.1002/eji.200838906
33. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De
Marchis F, et al. Mutually exclusive redox forms of HMGB1 promote
cell recruitment or proinflammatory cytokine release. J Exp Med. (2012)
209:1519–28. doi: 10.1084/jem.20120189
34. Bianchi ME, Crippa MP, Manfredi AA, Mezzapelle R, Rovere QP, Venereau
E. High-mobility group box 1 protein orchestrates responses to tissue damage
via inflammation, innate and adaptive immunity, and tissue repair. Immunol
Rev. (2017) 280:74–82. doi: 10.1111/imr.12601
35. Mukherjee D, Zhao J. The role of chemokine receptor CXCR4 in breast cancer
metastasis. Am J Cancer Res. (2013) 3:46–57.
36. Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4:
a symbiotic bridge linking cancer cells and their stromal neighbors
in oncogenic communication networks. Oncogene (2016) 35:816–26.
doi: 10.1038/onc.2015.139
37. Venereau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front
Immunol. (2015) 6:422. doi: 10.3389/fimmu.2015.00422
38. Venereau E, Schiraldi M, Uguccioni M, Bianchi ME. HMGB1 and leukocyte
migration during trauma and sterile inflammation. Mol Immunol. (2013)
55:76–82. doi: 10.1016/j.molimm.2012.10.037
39. Ferreira TP, Mariano LL, Ghilosso-Bortolini R, de Arantes AC, Fernandes
AJ, Berni M, et al. Potential of PEGylated toll-like receptor 7 ligands for
controlling inflammation and functional changes in mouse models of asthma
and silicosis. Front Immunol. (2016) 7:95. doi: 10.3389/fimmu.2016.00095
40. Shaul ME, Fridlender ZG. Cancer related circulating and tumor-
associated neutrophils - subtypes, sources and function. FEBS J. (2018).
doi: 10.1111/febs.14524. [Epub ahead of print].
41. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated
macrophages as treatment targets in oncology. Nat Rev Clin Oncol. (2017)
14:399–416. doi: 10.1038/nrclinonc.2016.217
42. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer
cells and natural killer T cells in cancer. Nat Rev Immunol. (2012) 12:239–52.
doi: 10.1038/nri3174
43. Ugel S, De SF, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation:
when myeloid-derived suppressor cells meet tumor-associated macrophages.
J Clin Invest. (2015) 125:3365–76. doi: 10.1172/JCI80006
44. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of
the immune system. Nat Rev Immunol. (2009) 9:162–74. doi: 10.1038/nri2506
45. Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. J Immunol.
(2018) 200:443–9. doi: 10.4049/jimmunol.1701024
46. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-
Pages C, et al. Type, density, and location of immune cells within human
colorectal tumors predict clinical outcome. Science (2006) 313:1960–4.
doi: 10.1126/science.1129139
47. Schwartz M, Zhang Y, Rosenblatt JD. B cell regulation of the anti-tumor
response and role in carcinogenesis. J Immunother Cancer. (2016) 4:40.
doi: 10.1186/s40425-016-0145-x
48. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer
microenvironment and their relevance in cancer immunotherapy. Nat
Rev Immunol. (2017) 17:559–72. doi: 10.1038/nri.2017.49
49. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al.
Clinical impact of different classes of infiltrating T cytotoxic and helper cells
(Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. (2011)
71:1263–71. doi: 10.1158/0008-5472.CAN-10-2907
50. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al.
Phenotype, distribution, generation, and functional and clinical relevance
of Th17 cells in the human tumor environments. Blood (2009) 114:1141–9.
doi: 10.1182/blood-2009-03-208249
51. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu
S, et al. T helper 17 cells promote cytotoxic T cell activation in
Frontiers in Immunology | www.frontiersin.org 6 September 2018 | Volume 9 | Article 2185
D’Agostino et al. Chemokines in Tumor Microenvironment
tumor immunity. Immunity (2009) 31:787–98. doi: 10.1016/j.immuni.2009.
09.014
52. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial
CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio
are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci
USA. (2005) 102:18538–43. doi: 10.1073/pnas.0509182102
53. Kistner L, Doll D, Holtorf A, Nitsche U, Janssen KP. Interferon-
inducible CXC-chemokines are crucial immune modulators and survival
predictors in colorectal cancer. Oncotarget (2017) 8:89998–90012.
doi: 10.18632/oncotarget.21286.
54. Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al.
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and
immunotherapy. Nature (2015) 527:249–53. doi: 10.1038/nature15520
55. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade
for cancer therapy: mechanisms, response biomarkers, and combinations. Sci
Transl Med. (2016) 8:328rv4. doi: 10.1126/scitranslmed.aad7118
56. Bronger H, Singer J, Windmuller C, Reuning U, Zech D, Delbridge C, et al.
CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase
inhibition in advanced serous ovarian cancer. Br J Cancer (2016) 115:553–63.
doi: 10.1038/bjc.2016.172
57. Fialova A, Partlova S, Sojka L, Hromadkova H, Brtnicky T, Fucikova J, et al.
Dynamics of T-cell infiltration during the course of ovarian cancer: the
gradual shift from a Th17 effector cell response to a predominant infiltration
by regulatory T-cells. Int J Cancer (2013) 132:1070–9. doi: 10.1002/ijc.27759
58. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al.
Macrophage activation and polarization: nomenclature and experimental
guidelines. Immunity (2014) 41:14–20. doi: 10.1016/j.immuni.2014.06.008
59. Oghumu S, Varikuti S, Terrazas C, Kotov D, Nasser MW, Powell CA, et al.
CXCR3 deficiency enhances tumor progression by promoting macrophage
M2 polarization in a murine breast cancer model. Immunology (2014)
143:109–19. doi: 10.1111/imm.12293
60. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of
tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN.
Cancer Cell (2009) 16:183–94. doi: 10.1016/j.ccr.2009.06.017
61. Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E, Manes S. Maximal
T cell-mediated antitumor responses rely upon CCR5 expression
in both CD4+ and CD8+ T cells. Cancer Res. (2011) 71:5455–66.
doi: 10.1158/0008-5472.CAN-11-1687
62. Ruytinx P, Proost P, Struyf S. CXCL4 and CXCL4L1 in cancer. Cytokine (2018)
109:65–71. doi: 10.1016/j.cyto.2018.02.022
63. Schmidt M, Bohm D, von TC, Steiner E, Puhl A, Pilch H, et al. The humoral
immune system has a key prognostic impact in node-negative breast cancer.
Cancer Res. (2008) 68:5405–13. doi: 10.1158/0008-5472.CAN-07-5206
64. Nedergaard BS, Ladekarl M, Nyengaard JR, Nielsen K. A comparative study
of the cellular immune response in patients with stage IB cervical squamous
cell carcinoma. Low numbers of several immune cell subtypes are strongly
associated with relapse of disease within 5 years. Gynecol Oncol. (2008)
108:106–11. doi: 10.1016/j.ygyno.2007.08.089
65. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, et al. Systematic
analysis of immune infiltrates in high-grade serous ovarian cancer reveals
CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009)
4:e6412. doi: 10.1371/journal.pone.0006412
66. Germain C, Gnjatic S, Dieu-Nosjean MC. Tertiary lymphoid structure-
associated B cells are key players in anti-tumor immunity. Front Immunol.
(2015) 6:67. doi: 10.3389/fimmu.2015.00067
67. Gu-Trantien C, Migliori E, Buisseret L, de WA, Brohee S, Garaud
S, et al. CXCL13-producing TFH cells link immune suppression and
adaptive memory in human breast cancer. JCI Insight (2017) 2:91487.
doi: 10.1172/jci.insight.91487
68. Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M,
Sammicheli S, et al. NK Cells Stimulate recruitment of cDC1 into the
tumor microenvironment promoting cancer immune control. Cell (2018)
172:1022–37. doi: 10.1016/j.cell.2018.01.004
69. Keeley EC, Mehrad B, Strieter RM. CXC chemokines in cancer
angiogenesis and metastases. Adv Cancer Res. (2010) 106:91–111.
doi: 10.1016/S0065-230X(10)06003-3
70. Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its
receptors CXCR1 and CXCR2 and their association with vessel density and
aggressiveness in malignant melanoma. Am J Clin Pathol. (2006) 125:209–16.
doi: 10.1309/VPL5-R3JR-7F1D-6V03
71. Wente MN, Keane MP, Burdick MD, Friess H, Buchler MW, Ceyhan GO,
et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic
cancer cell-induced angiogenesis. Cancer Lett. (2006) 241:221–7.
doi: 10.1016/j.canlet.2005.10.041
72. Gijsbers K, Gouwy M, Struyf S, Wuyts A, Proost P, Opdenakker G, et al.
GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in
neutrophil mobilization and is associated with angiogenesis in gastrointestinal
tumors. Exp Cell Res. (2005) 303:331–42. doi: 10.1016/j.yexcr.2004.09.027
73. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM.
The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma.
J Immunol. (2005) 175:5351–7. doi: 10.4049/jimmunol.175.8.5351
74. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters
immune privilege and predicts reduced survival. Nat Med. (2004) 10:942–9.
doi: 10.1038/nm1093
75. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al.
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg)
cells. Nature (2011) 475:226–30. doi: 10.1038/nature10169
76. Wiedemann GM, Knott MM, Vetter VK, Rapp M, Haubner S,
Fesseler J, et al. Cancer cell-derived IL-1alpha induces CCL22 and the
recruitment of regulatory T cells. Oncoimmunology (2016) 5:e1175794.
doi: 10.1080/2162402X.2016.1175794
77. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL,
et al. Breast cancer lung metastasis requires expression of chemokine
receptor CCR4 and regulatory T cells. Cancer Res. (2009) 69:5996–6004.
doi: 10.1158/0008-5472.CAN-08-4619
78. Redjimi N, Raffin C, Raimbaud I, Pignon P, Matsuzaki J, Odunsi K,
et al. CXCR3+ T regulatory cells selectively accumulate in human ovarian
carcinomas to limit type I immunity. Cancer Res. (2012) 72:4351–60.
doi: 10.1158/0008-5472.CAN-12-0579
79. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev
Immunol. (2006) 6:295–307. doi: 10.1038/nri1806
80. Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L, et al. Regulatory T cells
in the bone marrow microenvironment in patients with prostate cancer.
Oncoimmunology (2012) 1:152–61. doi: 10.4161/onci.1.2.18480
81. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of
interleukin 22 but not interleukin 17 by a subset of human skin-homing
memory T cells. Nat Immunol. (2009) 10:857–63. doi: 10.1038/ni.1767
82. Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, et al. IL-22+CD4+
T cells promote colorectal cancer stemness via STAT3 transcription factor
activation and induction of the methyltransferase DOT1L. Immunity (2014)
40:772–84. doi: 10.1016/j.immuni.2014.03.010
83. Sun D, Lin Y, Hong J, Chen H, Nagarsheth N, Peng D, et al.
Th22 cells control colon tumorigenesis through STAT3 and Polycomb
Repression complex 2 signaling. Oncoimmunology (2016) 5:e1082704.
doi: 10.1080/2162402X.2015.1082704
84. Balkwill F, Montfort A, Capasso M. B regulatory cells in cancer. Trends
Immunol. (2013) 34:169–73. doi: 10.1016/j.it.2012.10.007
85. Mauri C, Menon M. Human regulatory B cells in health and disease:
therapeutic potential. J Clin Invest. (2017) 127:772–9. doi: 10.1172/JCI85113
86. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res.
(2008) 14:6735–41. doi: 10.1158/1078-0432.CCR-07-4843
87. Pollard JW. Trophic macrophages in development and disease. Nat Rev
Immunol. (2009) 9:259–70. doi: 10.1038/nri2528
88. Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, et al.
CCL2-induced chemokine cascade promotes breast cancer metastasis by
enhancing retention of metastasis-associated macrophages. J Exp Med. (2015)
212:1043–59. doi: 10.1084/jem.20141836
89. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky
V, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells
mediate CCR5-dependent recruitment of regulatory T cells favoring
tumor growth. J Immunol. (2012) 189:5602–11. doi: 10.4049/jimmunol.12
01018
90. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M.
The chemokine system in diverse forms of macrophage activation and
polarization. Trends Immunol. (2004) 25:677–86. doi: 10.1016/j.it.2004.09.015
Frontiers in Immunology | www.frontiersin.org 7 September 2018 | Volume 9 | Article 2185
D’Agostino et al. Chemokines in Tumor Microenvironment
91. Zou W, Machelon V, Coulomb-L’Hermin A, Borvak J, Nome F, Isaeva
T, et al. Stromal-derived factor-1 in human tumors recruits and alters
the function of plasmacytoid precursor dendritic cells. Nat Med. (2001)
7:1339–46. doi: 10.1038/nm1201-1339
92. Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, et al. Plasmacytoid
dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.
Cancer Res. (2005) 65:5020–6. doi: 10.1158/0008-5472.CAN-04-4043
93. Vanbervliet B, Bendriss-Vermare N, Massacrier C, Homey B, de Bouteiller O,
Briere F, et al. The inducible CXCR3 ligands control plasmacytoid dendritic
cell responsiveness to the constitutive chemokine stromal cell-derived factor 1
(SDF-1)/CXCL12. J Exp Med. (2003) 198:823–30. doi: 10.1084/jem.20020437
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 D’Agostino, Cecchinato and Uguccioni. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 8 September 2018 | Volume 9 | Article 2185
